New TB drug combo shows promise in early trial

NCT ID NCT04550832

Completed Disease control Sponsor: LigaChem Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase IIb trial tested an experimental antibiotic called delpazolid, added to a standard three-drug regimen (bedaquiline, delamanid, moxifloxacin), in 76 adults with newly diagnosed, drug-sensitive pulmonary tuberculosis. The main goals were to check safety and how the drug levels in the body relate to its effects. Results help determine the right dose for future studies, but the trial was not designed to prove a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delpazolid (an experimental antibiotic) combined with bedaquiline, delamanid, and moxifloxacin
What this could lead to: If successful, this could lead to a shorter, more effective treatment regimen for drug-sensitive tuberculosis.
What could go wrong: This is a small, early-phase trial (76 participants) focused on safety and dosing, not on cure rates. The experimental drug is not yet licensed, and side effects or lack of added benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS AND INFESTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIONS AND INFESTATIONS PULMONARY TUBERCULOSIS

Contacts and locations

Locations

Clinical HIV Research Unit (CHRU) University of the Witwatersrand

Johannesburg, 2092, South Africa
Ifakara Health Institute

Bagamoyo, Tanzania
Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI)

Moshi, Tanzania
National Institute for Medical Research (NIMR-MMRC)

Mbeya, Tanzania
The Aurum Institute Tembisa Clinical Research Centre

Tembisa, Gauteng, 1632, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.